company background image
NGEN logo

NervGen Pharma TSXV:NGEN Stock Report

Last Price

CA$3.00

Market Cap

CA$220.1m

7D

9.9%

1Y

44.9%

Updated

20 Dec, 2024

Data

Company Financials +

NGEN Stock Overview

Engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. More details

NGEN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

NervGen Pharma Corp. Competitors

Price History & Performance

Summary of share price highs, lows and changes for NervGen Pharma
Historical stock prices
Current Share PriceCA$3.00
52 Week HighCA$3.98
52 Week LowCA$1.65
Beta1.44
1 Month Change33.93%
3 Month Change9.49%
1 Year Change44.93%
3 Year Change14.07%
5 Year Change71.43%
Change since IPO72.41%

Recent News & Updates

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Oct 23
We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Recent updates

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Oct 23
We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Jun 11
We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth?

Dec 22
Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth?

Here's Why We're Watching NervGen Pharma's (CVE:NGEN) Cash Burn Situation

Aug 30
Here's Why We're Watching NervGen Pharma's (CVE:NGEN) Cash Burn Situation

Will NervGen Pharma (CVE:NGEN) Spend Its Cash Wisely?

Apr 04
Will NervGen Pharma (CVE:NGEN) Spend Its Cash Wisely?

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

Feb 02
NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Nov 23
We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

Jun 29
We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 16
We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 08
We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Shareholder Returns

NGENCA PharmaceuticalsCA Market
7D9.9%-1.2%-3.7%
1Y44.9%-24.4%15.0%

Return vs Industry: NGEN exceeded the Canadian Pharmaceuticals industry which returned -24.4% over the past year.

Return vs Market: NGEN exceeded the Canadian Market which returned 15% over the past year.

Price Volatility

Is NGEN's price volatile compared to industry and market?
NGEN volatility
NGEN Average Weekly Movement13.4%
Pharmaceuticals Industry Average Movement12.0%
Market Average Movement8.2%
10% most volatile stocks in CA Market17.6%
10% least volatile stocks in CA Market2.9%

Stable Share Price: NGEN's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: NGEN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
2017n/aMike Kellywww.nervgen.com

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer’s disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage.

NervGen Pharma Corp. Fundamentals Summary

How do NervGen Pharma's earnings and revenue compare to its market cap?
NGEN fundamental statistics
Market capCA$220.06m
Earnings (TTM)-CA$24.01m
Revenue (TTM)n/a

0.0x

P/S Ratio

-8.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NGEN income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$24.01m
Earnings-CA$24.01m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.34
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NGEN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 02:05
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NervGen Pharma Corp. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chelsea StellickiA Capital Markets
Scott McAuleyParadigm Capital, Inc.
Justin KeywoodStifel Canada